The 2026 Nobel Prize in physiology or medicine has been awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel. The trio was honored for their pioneering development of optogenetics, a technique that provides unprecedented insight into the brain’s complex inner workings.
Optogenetics functions as a “light-sensitive switch,” enabling scientists to precisely “map which cells are responsible for which function” within the brain, according to Anna Wedell, a member of the Nobel committee. The research trajectory began with German scientists Hegemann, 71, and Nagel, 73, who identified channelrhodopsin, a protein found in single-celled algae that is both light-sensitive and capable of generating electrical impulses. American neurosurgeon and researcher Karl Deisseroth, 54, later transformed this protein into a specialized switch to control nerve cells, effectively laying the groundwork for a transformative era in neuroscience. That work has “laid the foundation for a new era in neuroscience,” the committee added. Which are able to swim towards a light source, the discovery began with Hegemann’s curiosity about the behavior of single-celled algae known as Chlamydomonas.
By introducing genes encoding this protein into neural circuits, researchers can now identify and manipulate the specific brain functions governing memories, feelings, and behaviors. In a breakthrough experiment around 2007, Deisseroth demonstrated that by illuminating specific nerve cells, he could control the movement of a mouse’s whiskers. This discovery has since allowed scientists to map neural pathways associated with pain, reward, food consumption, social interaction, thirst, and attention.
The impact of this technology extends deep into clinical research. Andrea Benucci, a professor of biology and experimental psychology at Queen Mary University of London, noted that the ability to silence or activate neurons with laser light has revolutionized the study of mental disorders. The field offers hope for future treatments concerning Parkinson’s, Alzheimer’s, schizophrenia, depression, and anxiety.
Clinical potential is already being tested in vision restoration for patients with retinitis pigmentosa. The Nobel committee reported that after inserting channelrhodopsin-like proteins into the retina of a blind individual, the patient regained enough vision to discern and grasp objects using light-emitting glasses. Similar research is currently exploring the use of optogenetics to enhance the efficacy of cochlear implants for those suffering from hearing loss. A disease that destroys the eye’s rods and cones, researchers in optogenetics are attempting to restore vision in people who have become blind due to retinitis pigmentosa.
The laureates were reportedly “very surprised” upon hearing the news. Thomas Perlmann, the committee’s secretary-general, recounted that Deisseroth was asleep when notified. Despite the sudden nature of the announcement, all three scientists expressed deep appreciation for sharing the honor. David Pendlebury, of Clarivate’s Institute for Scientific Information, described the award as a validation of a field that has fundamentally altered the scientific understanding of the nervous system. According to “Karl Deisseroth was very tired when he answered, he was definitely asleep, but he woke up … All three, The same thing, that they thought it was absolutely wonderful to receive the prize with the other two,” Perlmann.
The recipients will split the 12 million Swedish krona (approximately $1,200,000) prize fund equally. This announcement marks the start of the Nobel week, with awards in physics, chemistry, literature, and peace to follow, concluding with the Nobel Memorial Prize in Economic Science on the following Monday. This story and its headline has been updated with additional reporting.